130798-51-5

中文名稱 MDL-29951

英文名稱 MDL-29951

CAS 130798-51-5

分子式 C12H9Cl2NO4

分子量 302.11

MOL 文件 130798-51-5.mol

更新日期 2026/07/18 15:37:13

130798-51-5 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 MDL-29951價(jià)格(試劑級(jí)) 常見問題列表

基本信息

中文別名

2-羧基-4,6-二氯-1H-吲哚-3-丙酸

英文別名

CS-1105
MDL-29951, >=98%
MDL-29951
MDL29951
2-Carboxy-4,6-dichloro-1H-indole-3-propanoic acid
2-Carboxy-4,6-dichloro-1H-indole-3-propionic acid
3-(2-carboxy-4,6-dichloroindol-3-yl)propionic acid
1H-Indole-3-propanoic acid, 2-carboxy-4,6-dichloro-
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid
MDL-29951 2-Carboxy-4,6-dichloro-1H-indole-3-propanoic acid

所屬類別

醫(yī)藥中間體：雜環(huán)化合物

物理化學(xué)性質(zhì)

熔點(diǎn)273-280℃

沸點(diǎn)582.5±45.0 °C(Predicted)

密度1.657±0.06 g/cm3(Predicted)

儲(chǔ)存條件Keep in dark place,Sealed in dry,2-8°C

溶解度可溶于DMSO（加熱時(shí)高達(dá)15mg/ml）或乙醇（高達(dá)10mg/ml）。

酸度系數(shù)(pKa)4.04±0.30(Predicted)

形態(tài)固體

顏色米白色

穩(wěn)定性DMSO或乙醇溶液可在-20°下穩(wěn)定儲(chǔ)存3個(gè)月。

安全數(shù)據(jù)

危險(xiǎn)性符號(hào)(GHS) 有害 (GHS07)

GHS07

警示詞警告

危險(xiǎn)性描述H302-H317

防范說明P280-P305+P351+P338

圖譜信息

MDL-29951(130798-51-5)核磁圖(¹HNMR)

MDL-29951價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱	CAS號(hào)	包裝	價(jià)格
2026/06/05	HY-16312	MDL-29951 MDL-29951	130798-51-5	1 mg	415元
2026/06/05	HY-16312	MDL-29951 MDL-29951	130798-51-5	5 mg	995元
2026/06/05	HY-16312	MDL-29951 MDL-29951	130798-51-5	10 mM * 1 mL in DMSO	1094元

常見問題列表

生物活性

MDL-29951 是一種新穎的 nMDA receptor 拮抗劑，能夠抑制體內(nèi)體外甘氨酸 ([3H]glycine) 的結(jié)合，Ki 值為 0.14 μM。

靶點(diǎn)

Ki: 0.14 μM

體外研究

MDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to the glutamate recognition sites. MDL-29951 is found to inhibit the human F16Bpase under these conditions (IC ₅₀ =2.5 μM). MDL-29951 inhibits the human liver (IC ₅₀ =2.5 μM), porcine kidney (IC ₅₀ =1.0 μM), and rabbit liver (IC ₅₀ =0.21 μM) isoforms of the enzyme, but is significantly less potent against the rat liver isoform (IC ₅₀ =11 μM). The MDL29951-activated receptor exhibits other activities associated with GPCR-mediated signaling, including G protein-dependent activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and recruitment of β-arrestin. As with recombinant cell systems, MDL29951 promotes Ca ²⁺ signaling responses and inhibition of cyclic adenosine monophosphate (cAMP) accumulation in rat oligodendrocyte precursor cells during the period of peak GPR17 abundance. Effects of MDL29951 are markedly reduced in cells with low GPR17 abundance and are blocked by pranlukast.